PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.
|
|
|
- Valerie Richardson
- 5 years ago
- Views:
Transcription
1 Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup interval and whenever there is a change in the patient's status. Dates are mm-dd-yyyy unless otherwise specified. 1 (1) VITAL STATUS 1 Alive 2 Dead 2 (2) - - DATE OF LAST CONTACT OR DEATH 3 (3) PRIMARY CAUSE OF DEATH 1 Due to this disease (whether local, regional, or distant) 2 Due to a second primary or other malignancy 3 Due to protocol treatment (explain in COMMENTS, requires a grade 5 toxicity code) 4 Due to other cause (describe cause of death in comment section) 5a (6) RESPONSE OF TARGET LESION AT THIS ASSESSMENT (TARGET VOLUME ONLY) 1 Complete Response (CR) 2 Partial Response (PR) 3 Stable Disease (SD) 4 Local Enlargement (LE) 5 Primary tumor failure (PTF) 6 Not evaluated 5b RESPONSE CONFIRMED DATE - - (7) 6 STATUS OF LESIONS OUTSIDE OF TARGET VOLUME(8) 0 Not evaluated 1 Disease present, answer all 4 items in 6b 2 Disease absent 6b STATUS DATE CONFIRMED 4a (4). kg WEIGHT 4b (5) PERFORMANCE STATUS (ZUBROD)(0-5, 9=Unknown) Marginal Failure (MF)(9) Involved lobe failure(100) Regional Failure (RF)(11) Metastatic Dissemination (MD)(13) - - (10) - - (101) - - (12) - - (14) 7 HAS PATIENT BEEN DIAGNOSED WITH A NEW PROGRESSION? (From this primary lung tumor) PROGRESSION 0 Not evaluated METHOD OF EVALUATION 0 Not applicable 1 Physical Exam 2 CT Scan 3 MRI Scan 4 PET Scan 5 Pathologic 6 Chest x-ray SITE OF PROGRESSION #1 #2 (15) Lung (Primary Site) (16) (17) (19) Lung (Primary, margin or stump) (20) (21) (23) Ipsilateral lung (Not primary site) (24) (25) (27) Contralateral lung (28) (29) (31) Regional lymph nodes (32) (33) (35) Pleura (36) (37) (39) Brain (40) (41) (43) CNS (Not brain) (44) (45) (47) Liver (48) (49) (51) Bone (52) (53) (55) Distant lymph nodes, specify(56) (57) (58) (60) Skin or subcutaneous, specify(61) (62) (63) (65) Other site, specify(66) (67) (68) DATE RESPONSE LAST DOCUMENTED (18) - - (22) - - (26) - - (30) - - (34) - - (38) - - (42) - - (46) - - (50) - - (54) - - (59) - - (64) - - (69) F1a of 5
2 8 HAS A NEW PRIMARY CANCER OR MDS (MYELODYSPLASTIC SYNDROME) BEEN DIAGNOSED THAT HAS NOT BEEN PREVIOUSLY REPORTED?(70) NEW PRIMARY SITE 11 Oral cavity 12 Oropharynx 13 Hypopharynx 14 Larynx 15 Nasopharynx 16 Other H + N 17 AML/MDS 18 BCC 19 Bladder 20 Brain 21 Colorectal 22 Esophageal 23 Gastric 24 Liver 25 Lung 26 Melanoma 27 NHL 28 Pancreatic 29 Renal 30 Squamous-Skin 31 Prostate 32 Other Hematologic 33 Other solid 34 Unknown primary METHOD OF EVALUATION 1 Physical Exam 2 CT Scan 3 MRI Scan 4 PET Scan 5 Pathologic 6 Chest x-ray SITES(S) OF NEW PRIMARY METHOD OF EVALUATION DATE OF DIAGNOSIS (71) (72) - - (73) (74) (75) - - (76) (77) (78) - - (79) 9 (80) WERE PULMONARY FUNCTION TESTS PERFORMED? Date - - (81) (82). BEST FORCED EXPIRATORY VOLUME 1 (FEV 1) L/SEC (83). % OF PREDICTED VALUE (FEV 1) (84). % OF CARBON MONOXIDE DIFFUSION (DLCO) (85). FORCED VITAL CAPACITY (FVC) L/sec (86). % OF PREDICTED FORCED VITAL CAPACITY 10 (87) IS THE PATIENT RECEIVING ANY NON-PROTOCOL CANCER THERAPY NOT PREVIOUSLY REPORTED? (code all boxes) (88) PCI (89) Non-Protocol Radiation Therapy (excluding PCI) (90) Non-Protocol Surgery (91) Non-Protocol Chemotherapy (92) Other Non-Protocol therapy (specify below): (93) 0813 F1a of 5
3 11 PROTOCOL SPECIFIC EVENTS DURING THIS PERIOD (94) (All events below must be coded) Protocol Specific Adverse Event Evaluation. Score most severe grade observed during report period (Grade 1-5). If the AE did not occur, code "0".. AE's > grade 3 require date of onset.. Assign attribution to protocol treatment for each AE reported; indicate whether SAE was submitted A. Attribution to Protocol Treatment 1 Unrelated 2 Unlikely 3 Possible 4 Probable 5 Definite B. SAE Report Submitted MedDRA 12 ADVERSE EVENT CODE CTCAE V4 TERM GRADE START DATE A B (301) (302) (303) - - (304) (305) (306) (307) (308) (309) - - (310) (311) (312) (313) (314) (315) - - (316) (317) (318) (319) (320) (321) - - (322) (323) (324) (325) (326) (327) - - (328) (329) (330) (331) (332) (333) - - (334) (335) (336) Pericardial effusion Pericarditis Restrictive cardiomyopathy Dysphagia Esophagitis Esophageal fistula Esophageal obstruction (337) (338) (339) - - (340) (341) (342) Esophageal perforation (343) (344) (345) - - (346) (347) (348) Esophageal stenosis (349) (350) (351) - - (352) (353) (354) Esophageal ulcer (355) (356) (357) - - (358) (359) (360) Esophageal hemorrhage (361) (362) (363) - - (364) (365) (366) Brachial plexopathy (367) (368) (369) - - (370) (371) (372) Recurrent laryngeal nerve palsy (373) (374) (375) - - (376) (377) (378) Myelitis (379) (380) (381) - - (382) (383) (384) Atelectasis (391) (392) (393) - - (394) (395) (396) Hypoxia (397) (398) (399) - - (400) (401) (402) Pleural effusion (403) (404) (405) - - (406) (407) (408) Pneumonitis (409) (410) (411) - - (412) (413) (414) Pulmonary fibrosis (415) (416) (417) - - (418) (419) (420) Bronchopulmonary hemorrhage (421) (422) (423) - - (424) (425) (426) 0813 F1a of 5
4 MedDRA 12 ADVERSE EVENT CODE CTCAE V4 TERM GRADE START DATE A B Mediastinal hemorrhage (439) (440) (441) - - (442) (443) (444) Pleural hemorrhage (445) (446) (447) - - (448) (449) (450) Tracheal hemorrhage (457) (458) (459) - - (460) (461) (462) Bronchial fistula (463) (464) (465) - - (466) (467) (468) Pulmonary fistula (469) (470) (471) - - (472) (473) (474) Bronchopleural fistula (475) (476) (477) - - (478) (479) (480 Tracheal fistula (481) (482) (483) - - (484) (485) (486) Bronchial obstruction (487) (488) (489) - - (490) (491) (492) Tracheal obstruction (493) (494) (495) - - (496) (497) (498) 0813 F1a of 5
5 12 ANY OTHER TREATMENT RELATED ADVERSE EVENTS?(95) Adverse Events: Use the CTCAE version 4 (MedDRA 12) to code all events. Score most severe grade observed during report period (grade 1-5). Adverse Events of grade 3 or higher require start date. Assign attribution to protocol treatment for each AE and indicate if an SAE was reported. A. Attribution to Protocol Treatment 1 Unrelated 2 Unlikely 3 Possible 4 Probable 5 Definite B. SAE Report Submitted Adverse Event Code CTCAE V4 Term Grade Start Date A B (499) (500) (501) - - (502) (503) (504) (505) (506) (507) - - (508) (509) (510) (511) (512) (513) - - (514) (515) (516) (517) (518) (519) - - (520) (521) (522) (523) (524) (525) - - (526) (527) (528) (529) (530) (531) - - (532) (533) (534) (535) (536) (537) - - (538) (539) (540) (541) (542) (543) - - (544) (545) (546) (547) (548) (549) - - (550) (551) (552) (553) (554) (555) - - (556) (557) (558) (559) (560) (561) - - (562) (563) (564) (565) (566) (567) - - (568) (569) (570) (571) (572) (573) - - (574) (575) (576) (577) (578) (579) - - (580) (581) (582) (583) (584) (585) - - (586) (587) (588) (589) (590) (591) - - (592) (593) (594) (595) (596) (597) - - (598) (599) (600) (601) (602) (603) - - (604) (605) (606) (607) (608) (609) - - (610) (611) (612) Comments (96-97) - - Signature of person completing this form (98) Date form originally completed (99) 0813 F1a of 5
PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II Nasopharyngeal Cancer Follow-Up Form
F1 AMENDED DATA Radiation Therapy Oncology Group Phase II Nasopharyngeal Cancer Follow-Up Form YES No INSTRUCTIONS: Submit this form at the appropriate follow-up interval and at death Dates are recorded
AJCC-NCRA Education Needs Assessment Results
AJCC-NCRA Education Needs Assessment Results Donna M. Gress, RHIT, CTR Survey Tool 1 Survey Development, Delivery, Analysis THANKS to NCRA for the following work Developed survey with input from partners
Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)
Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded
Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Bronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
An Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2
FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
Collecting Cancer Data: Lung
Collecting Cancer Data: Lung NAACCR 2011 2012 Webinar Series 2/2/2012 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this
Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
Respiratory Interactive Session. Elaine Borg
Respiratory Interactive Session Elaine Borg Case 1 Respiratory Cytology 55 year old gentleman Anterior mediastinal mass EBUS FNA Case 1 Respiratory Cytology 55 year old gentleman with anterior mediastinal
PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET
Positron Emission Tomography (PET) When calling Anthem (1-800-533-1120) or using the Point of Care authorization system for a Health Service Review, the following clinical information may be needed to
Clinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
The 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
and Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:
GROUP 1: Including: Excluding: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases Solid pulmonary nodules 8mm diameter / 300mm3 volume and BROCK risk of malignancy
PET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
Lung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo
Lung Cancer-a primer Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo CLINICAL CATEGORIES THE SOLITARY PULMONARY NODULE MULTIPLE PULMONARY NODULES Differential Diagnosis Malignant
TB Intensive Houston, Texas
TB Intensive Houston, Texas October 15-17, 17 2013 Diagnosis of TB: Radiology Rosa M Estrada-Y-Martin, MD MSc FCCP October 16, 2013 Rosa M Estrada-Y-Martin, MD MSc FCCP, has the following disclosures to
GUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
Radiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
Collaborative Stage. Site-Specific Instructions - LUNG
Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each
6 th Reprint Handbook Pages AJCC 7 th Edition
6 th Reprint Handbook Pages AJCC 7 th Edition AJCC 7 th Edition Errata for 6 th Reprint Table 1 Handbook No Significant Staging Clarifications for 6 th Reprint AJCC 7 th Edition Errata for 6 th Reprint
Surgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
THORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery
Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A
original report abstract
original report Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial Andrea Bezjak, MD 1 ; Rebecca
Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
Lung /1/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:
1 NAACCR 2015-2016 Webinar Series Collecting Cancer Data: Lung NAACCR 2015 2016 Webinar Series Presented by: Angela Martin amartin@naaccr.org Jim Hofferkamp jhofferkamp@naaccr.org Q&A Please submit all
PET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
Lung Cancer Radiotherapy
Lung Cancer Radiotherapy Indications, Outcomes, and Impact on Survivorship Care Malcolm Mattes, MD Assistant Professor WVU Department of Radiation Oncology When people think about radiation, they think
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer. Doug Rahn 6/1/12
Case Conference: Post-Operative Radiotherapy for Non-Small Cell Lung Cancer Doug Rahn 6/1/12 Outline I. Presentation of Case II. Epidemiology III. Staging IV. Review of Literature V. Recommendations VI.
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the highest incidence
LUNG CANCER 2010 Mark B. Stoopler, M.D. Division of Medical Oncology Lung Cancer Very common Very lethal Median age of diagnosis i approximately 70 years, but affects all ages In the United States, the
Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.
N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted 10 Salvage surgery for local failures after stereotactic
3/30/2009 Lung Cancer Deaths 2008 Lung Cancer Deaths Lung Cancer Deaths--Males Males 5
LUNG CANCER 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Very common Very lethal Lung Cancer Median age of diagnosis approximately 70 years, but affects all ages(even pediatric!) Advances in
Lung Cancer Incidence 2008 Lung Cancer Deaths-Males 2008 Incidence Total U.S.(all types): 1,437,180 Lung Cancer Deaths-Females Lung cancer 215,000(15%
Multidisciplinary approach 2009 Mark B. Stoopler, M.D. Division of Medical Oncology Neurology Neurosurgery Orthopedic surgery General surgery Vascular surgery Gastroenterology Cardiology Lung Cancer Very
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
RF Ablation: indication, technique and imaging follow-up
RF Ablation: indication, technique and imaging follow-up Trongtum Tongdee, M.D. Radiology Department, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Objective Basic knowledge
Adam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
Lung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD
Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive
Controversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
Lung 8/7/14. Collecting Cancer Data: Lung NAACCR Webinar Series. August 7, 2014
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
PULMONARY TUBERCULOSIS RADIOLOGY
PULMONARY TUBERCULOSIS RADIOLOGY RADIOLOGICAL MODALITIES Medical radiophotography Radiography Fluoroscopy Linear (conventional) tomography Computed tomography Pulmonary angiography, bronchography Ultrasonography,
Cancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
The Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
PRINCIPLES OF RADIATION ONCOLOGY
PRINCIPLES OF RADIATION ONCOLOGY Ravi Pachigolla, MD Faculty Advisor: Anna Pou, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation January 5, 2000 HISTORY
Video-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Welcome to the RECIST 1.1 Quick Reference
Welcome to the RECIST 1.1 Quick Reference *Eisenhauer, E. A., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. Subject Eligibility
Imaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung
Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is
A 64 y.o. man presents to the hospital with persistent cough and hemoptysis. Fernando Mut Montevideo - Uruguay
A 64 y.o. man presents to the hospital with persistent cough and hemoptysis Fernando Mut Montevideo - Uruguay Teaching case Bone # 1 A 64 y.o. man presents to the hospital with persistent cough and hemoptysis.
PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease
PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease Refer back to original requester with this paperwork and review previous
Thoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
The Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
Safe Answers For The American Board of Surgery Certifying Exam & Recertifying Exam
Safe Answers For The American Board of Surgery Certifying Exam & Recertifying Exam By Sarmad Aji, MD., FACS. A comprehensive review of the most commonly asked questions on the American Board of Surgery
Malignant Effusions. Anantham Devanand Respiratory and Critical Care Medicine Singapore General Hospital
Malignant Effusions Anantham Devanand Respiratory and Critical Care Medicine Singapore General Hospital Malignant Effusions Definition: Presence of malignant cells in the pleural space 75% are caused by
- In potentially operable patients -
Lung Stereotactic Ablative Radiotherapy (SABR) - In potentially operable patients - Frank Lagerwaard VUMC Amsterdam Stereotactic Ablative Radiotherapy (SABR) 2003-2008 4DCT-based target definition Non-gated
NATIONAL QUALITY FORUM
Cancer Endorsement Maintenance Table of Submitted Measures Phase I 0210 1 Proportion receiving chemotherapy in the last 14 days of life Percentage of patients who died from cancer receiving chemotherapy
Rola brachyterapii w leczeniu wznów nowotworów języka i dna jamy ustnej. The role of brachytherapy in recurrent. oral cavity
Rola brachyterapii w leczeniu wznów nowotworów języka i dna jamy ustnej The role of brachytherapy in recurrent tumours of the tongue and fundus of the oral cavity Janusz Skowronek, MD, PhD, Ass. Prof.
PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx
Radiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
Institution INSTRUCTIONS (I6) 1. This form is to be completed by a DESIGNATED STUDY NUCLEAR MEDICINE SPECIALIST
I6 ACRIN 6660 Whole Body MRI in the Evaluation of Pediatric Malignancies Conventional Scintigraphy Imaging Form If this is a revised or corrected form, indicate by checking box and fax to 215-717 - 0936.
Lung Cancer - Suspected
Lung Cancer - Suspected Shared Decision Making Lung Cancer: http://www.enhertsccg.nhs.uk/ Patient presents with abnormal CXR Lung cancer - clinical presentation History and Examination Incidental finding
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.
Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and
The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
Diagnosis of TB: Radiology David Finlay, MD
TB Intensive Tyler, Texas June 2-4, 2010 Diagnosis of TB: Radiology David Finlay, MD June 3, 2010 2stages stages- Tuberculosis 1. primary infection 2. reactivation, or post primary disease 2 1 Primary
ACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)
No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis
Cancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
ACR TXIT TM EXAM OUTLINE
ACR TXIT TM EXAM OUTLINE Major Domain Sub-Domain 1 Statistics 1.1 Study design 1.2 Definitions of statistical terms 1.3 General interpretation & analysis 1.4 Survival curves 1.5 Specificity/sensitivity
Thoracic complications post stereotactic body radiotherapy (SBRT) for lung cancer - what the radiologist needs to know
Thoracic complications post stereotactic body radiotherapy (SBRT) for lung cancer - what the radiologist needs to know Poster No.: C-1700 Congress: ECR 2014 Type: Educational Exhibit Authors: G. E. Khanda,
Preoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD
ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy
Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes
Review Article Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes J. Isabelle Choi Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
Practice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE LIFE THROUGH MEDICAL MEDICAL EDUCATION EDUCATION www.excemed.org
Update in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS
THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management
WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds
WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY RADIATION CHEMORADIATION? Dr. Paul Gardiner April 23, 2001 Discipline of Surgery Grand Rounds LUNG Dr. Greenland ESOPHAGUS Dr. Gardiner ESOPHAGEAL CANCER 1200 new
Evaluation of Cancer Outcomes Barwon South West Registry
Evaluation of Cancer Outcomes Barwon South West Registry Data Request Form Applicant details Applicant name: Position: Email: Project start date: Date: Telephone: Project completion date: Project details
NAACCR Webinar Series 1
Collecting Cancer Data: Lung 2013 2014 NAACCR Webinar Series August 7, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/CT
NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/CT NCCN guidelines were reviewed on 2/14/2016 for utilization of 18F-fluorodeoxyglucose (FDG) PET and PET/CT (available at:
A Case Report Form Packet Contents
A011502 Case Report Form Packet Contents Revision History... 3 Institutional Contacts... 4 On-Study (page 1 of 2)... 5 On-Study (page 2 of 2)... 6 Surgery: Left Breast (page 1 of 2)... 7 Surgery: Left
performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
Chief Complain. For chemotherapy
Chief Complain For chemotherapy Present Illness 93.12 Progressive weakness of R t arm for 1 year X-ray: peneative lesion over right proximal humorous Bone scan: multiple increased intake Biopsy of distal